Physician profile
Samantha Devlin
NPI 1750732616
$4,852.04
in general payments reported to CMS, 2019-2025
23 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $71.56 · 2021: $572 · 2022: $671 · 2023: $1,071 · 2024: $1,160 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,428.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,370.08 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Glaukos Corporation | $713.52 | 2021-2025 | Ce-Marked Kxla System, Idose |
| Johnson & Johnson Vision Care, INC. | $654.89 | 2021-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $389.50 | 2022-2025 | Miebo, Vyzulta, Infuse |
| Alcon Vision LLC | $389.17 | 2020-2025 | Dailies Total1, Hydrus Microstent, Total30 |
| Allergan, INC. | $236.31 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $213.43 | 2024-2025 | Xdemvy |
| Coopervision INC. | $127.52 | 2021-2024 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.07 | 2019-2021 | |
| Ocular Therapeutix, INC. | $98.05 | 2024 | Dextenza |
| Horizon Therapeutics Plc | $97.95 | 2022 | |
| Rxsight INC | $92.69 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Regeneron Pharmaceuticals, INC. | $71.24 | 2023 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $42.11 | 2019 | |
| Biotissue Holdings INC. | $40.38 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $37.46 | 2023-2024 | Tyrvaya, Ryzumvi |
| Ani Pharmaceuticals, INC. | $31.01 | 2024 | Purified Cortrophin Gel |
| Harrow Eye, LLC | $28.13 | 2025 | |
| The Cameron-Ehlen Group, INC. | $20.50 | 2021 | |
| Aerie Pharmaceuticals, INC. | $19.35 | 2020 | |
| Dompe US, INC. | $17.52 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $17.10 | 2025 | |
| Kala Pharmaceuticals, INC. | $17.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.